MedTrace Logo

Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia

NCT01863225 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2015-05-12

No results posted yet for this study

Summary

This study is designed to characterize the pharmacokinetics of multi-dose RVX000222 and atorvastatin and rosuvastatin when either statin is administered in combination with RVX000222 in subjects with dyslipidemia.

Conditions

Interventions

DRUG

RVX000222

capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 14-days

DRUG

Rosuvastatin

20 mg daily, 28-42 days

DRUG

Atorvastatin

40 mg daily, 28-42 days

DRUG

Rosuvastatin

40 mg daily, 28-42 days

DRUG

Atorvastatin

80 mg daily, 28-42 days

Sponsors & Collaborators

  • South Australian Health and Medical Research Institute

    collaborator OTHER

  • Resverlogix Corp

    lead INDUSTRY

Principal Investigators

  • Dr. Sepehr Shakib · Royal Adelaide Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01863225 on ClinicalTrials.gov